Total EPS 11.2p, -48% AER, -33% CER; Adjusted EPS 24.6p, -2% AER, +11% CER
Kevin Sin appointed as Senior Vice President and Head of Worldwide Business Development for Pharmaceuticals Research & Development.
GSK signs strategic agreement to transfer rare disease gene therapy portfolio to Orchard Therapeutics
Agreement strengthens Orchard’s position as a global leader in gene therapy for rare diseases. GSK takes 19.9% equity stake in Orchard and seat on board.
GlaxoSmithKline plc (LSE/NYSE: GSK) today confirms it has withdrawn from the process relating to Pfizer’s Consumer Healthcare business.
ViiV Healthcare today announced that the European Committee for Medicinal Products for Human Use has issued a Positive Opinion recommending marketing authorisation for Juluca.